Michael Starkweather - Shuttle Pharmaceuticals VP Devel
| SHPH Stock | USD 0.85 0.02 2.30% |
Insider
Michael Starkweather is VP Devel of Shuttle Pharmaceuticals
| Age | 40 |
| Address | 401 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | (240) 403-4212 |
| Web | https://www.shuttlepharma.com |
Shuttle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.6169) % which means that it has lost $0.6169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.86) %, meaning that it created substantial loss on money invested by shareholders. Shuttle Pharmaceuticals' management efficiency ratios could be used to measure how well Shuttle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.16. The current Return On Capital Employed is estimated to decrease to -1.26. As of now, Shuttle Pharmaceuticals' Net Tangible Assets are increasing as compared to previous years. The Shuttle Pharmaceuticals' current Total Current Assets is estimated to increase to about 5.9 M, while Other Assets are projected to decrease to 5,184.Similar Executives
| Showing other executives | INSIDER Age | ||
| Denise Faltischek | Tilray Inc | 51 | |
| Ernest Galvan | Journey Medical Corp | 62 | |
| Dara Redler | Tilray Inc | N/A | |
| CPA CPA | Journey Medical Corp | 69 | |
| Patrick Bilbo | Organogenesis Holdings | 62 | |
| CA CBV | Tilray Inc | 52 | |
| Robyn Hunter | Journey Medical Corp | N/A | |
| Z Mahdavi | Catalent | N/A | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
| Karen Santiago | Catalent | 53 | |
| David Francisco | Organogenesis Holdings | 58 | |
| James Meiers | Tilray Inc | 66 | |
| Aaron Perlitsh | Lifecore Biomedical | N/A | |
| Karen Flynn | Catalent | 56 | |
| Julien Meissonnier | Catalent | N/A | |
| BA Esq | Organogenesis Holdings | 55 | |
| Albert Bolles | Lifecore Biomedical | 66 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Ricci Whitlow | Catalent | 51 | |
| Thomas Flow | Akanda Corp | 46 | |
| Michael Grippo | Catalent | 55 | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.62 |
Shuttle Pharmaceuticals Leadership Team
Elected by the shareholders, the Shuttle Pharmaceuticals' board of directors comprises two types of representatives: Shuttle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shuttle. The board's role is to monitor Shuttle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Shuttle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shuttle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, President COO | ||
| Michael Starkweather, VP Devel | ||
| CSC MD, Chief CoFounder | ||
| Timothy CPA, Chief Officer | ||
| Gene Esq, General Counsel | ||
| Mira Jung, CoFounder Biology | ||
| Tyvin MD, Chief Officer | ||
| Anatoly MD, MD, CoFounder | ||
| Michael Hoek, CFO Regulatory |
Shuttle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shuttle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | 3.52 M | ||||
| Shares Outstanding | 3.66 M | ||||
| Shares Owned By Insiders | 27.80 % | ||||
| Shares Owned By Institutions | 1.81 % | ||||
| Number Of Shares Shorted | 58.92 K | ||||
| Price To Book | 4.16 X | ||||
| EBITDA | (5.89 M) | ||||
| Net Income | (6.59 M) |
Currently Active Assets on Macroaxis
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.25) | Return On Assets (0.62) | Return On Equity (1.86) |
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.